Featured News

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.

The Celiac Disease Foundation’s article, “New Legislation Aims to Extend Nutrition Care to Chronic Conditions” was featured in Future of Personal Health.

I am thankful for your support, which has allowed the Celiac Disease Foundation to make a meaningful difference in the lives of our celiac community. 

Patients Who Have Participated In a Celiac Disease Clinical Trial Needed for 2021 Patient Education & Advocacy Summit.

One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s celiac disease patient registry. This month, researchers published three important studies that used iCureCeliac® as the data source.

New research from Columbia University revealed differences in the antibodies present, adding evidence that NCGS involves a different kind of inflammation in the gut in response to gluten.

The first study of its kind in North America has found an increased risk for birth defects in children of women with active, untreated celiac disease.

The Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).

Securing public and private health insurance coverage of Medical Nutrition Therapy (MNT) for celiac disease patients has been a long-time priority of the Celiac Disease Foundation.